Literature DB >> 11748658

High prevalence of hepatitis E antibodies among Danish prisoners and drug users.

Peer B Christensen1, Ronald E Engle, Svend Erik H Jacobsen, Henrik B Krarup, Jørgen Georgsen, Robert H Purcell.   

Abstract

Injecting drug users and prisoners have high prevalences of antibodies to hepatitis A-C. The aim of this study was to determine the prevalence of antibodies to hepatitis E virus (anti-HEV) in two Danish high-risk populations and correlate anti-HEV with risk factors for transmission. Three hundred thirty male prisoners and 137 patients at a drug treatment center were tested for anti-HEV with an in-house enzyme-linked immunoassay (EIA) utilizing antigens derived from open reading frame 2 (ORF2). This was compared with a commercial test with antigens derived from ORF2 and ORF3 (Abbott HEV EIA). In addition the samples were tested for antibodies against hepatitis A-C viruses, human immunodeficiency virus (HIV) 1 and 2, human T lymphotropic virus (HTLV) I and II and herpes simplex virus type 2 (HSV2). The participants were interviewed about risk factors for transmission. The anti-HEV prevalence was 16.9% (95% CI 14-21) for the in-house assay compared to 4.1% (95% CI 2.5-6.3) with the commercial assay. The correlation between the two assays was low (87% overall agreement; kappa value 0.32). One sample was strongly anti-HEV IgM positive, suggesting recent HEV infection inside Denmark. The presence of anti-HEV was associated significantly with anti-HAV among prisoners and increased with age in both groups. In contrast, associations were not found with injecting drug use or sexual risk factors. With the commercial assay an increased prevalence of anti-HEV was found among participants who had spent more than 5 years outside Northern Europe. In conclusion, anti-HEV was highly prevalent among Danish prisoners and drug users but not related to risk factors for blood-borne or sexual transmission. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748658     DOI: 10.1002/jmv.2110

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  20 in total

1.  Hepatitis E: are psychiatric patients on special risk?

Authors:  Claudia Reinheimer; Regina Allwinn; Annemarie Berger
Journal:  Med Microbiol Immunol       Date:  2011-10-18       Impact factor: 3.402

Review 2.  [Sexually transmissible hepatitis viruses].

Authors:  S Schaefer
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751

Review 3.  Host immune status and response to hepatitis E virus infection.

Authors:  Lisa J Krain; Kenrad E Nelson; Alain B Labrique
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

4.  Evaluation of diagnostic assays for hepatitis E virus in outbreak settings.

Authors:  Khin Saw Aye Myint; Timothy P Endy; Robert V Gibbons; Kanti Laras; Mammen P Mammen; Endang R Sedyaningsih; Jitvimol Seriwatana; Jonathan S Glass; Sumitda Narupiti; Andrew L Corwin
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

5.  Routes of transmission of swine hepatitis E virus in pigs.

Authors:  C Kasorndorkbua; D K Guenette; F F Huang; P J Thomas; X-J Meng; P G Halbur
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

6.  Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark.

Authors:  Peer B Christensen; Ronald E Engle; Charlotte Hjort; Keld M Homburg; Werner Vach; Jørgen Georgsen; Robert H Purcell
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

7.  Immunologically silent autochthonous acute hepatitis E virus infection in France.

Authors:  Jean Michel Mansuy; Jean Marie Peron; Christophe Bureau; Laurent Alric; Jean Pierre Vinel; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

Review 8.  Epidemiology of hepatitis E virus in Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Gastroenterol       Date:  2016-06-14       Impact factor: 5.742

9.  Characterization of hepatitis E-specific cell-mediated immune response using IFN-gamma ELISPOT assay.

Authors:  M T Shata; A Barrett; N J Shire; S F Abdelwahab; M Sobhy; E Daef; S S El-Kamary; M Hashem; R E Engle; R H Purcell; S U Emerson; G T Strickland; K E Sherman
Journal:  J Immunol Methods       Date:  2007-09-19       Impact factor: 2.303

10.  Hepatitis E: a complex and global disease.

Authors:  E Pelosi; I Clarke
Journal:  Emerg Health Threats J       Date:  2008-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.